Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Placebo ELLIPTA; Drug: Nemiralisib ELLIPTA 50 µg; Drug: Nemiralisib ELLIPTA 100 µg; Drug: Nemiralisib ELLIPTA 250 µg; Drug: Nemiralisib ELLIPTA 500 µg; Drug: Nemiralisib ELLIPTA 750 µg; Drug: Albuterol (Salbutamol) MDI or nebules; Drug: Standard of care therapy Sponsor: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Study